Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Chronic Obstructive Pulmonary Diseases (COPD)

Chronic Obstructive Pulmonary Diseases (COPD) are a group of lung diseases characterized by obstruction to airflow that interferes with normal breathing. COPD includes diseases such as chronic bronchitis, emphysema, and bronchiectasis.

COPD is a leading cause of illness, disability, and death in the US, where in 2005 up to 24 million adults are either diagnosed or exhibited signs of COPD, leading to 119,000 deaths. Acute exacerbations in COPD patients account for over 1.5 million emergency room visits annually, contributing to over $43 billion in medical care costs in the US in 2007.

Gram negatives are significant pathogens associated with COPD patients undergoing execerbation episodes. In a recent study*, up to 31% of the execerbation patients are infected with Pseudomonas aeruginosa, which may be amenable to treatment with both AerucinTM and PanaecinTM.

*Murphy, et al. 2008 Am. J. Resp. & Crit. Care Med. 177:853-860


Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis Home